<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - DACLATASVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>DACLATASVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with sofosbuvir for the treatment of chronic hepatitis C infection of genotypes 1 or 4, with or without compensated cirrhosis</span>,
                <span class="indication">In combination with sofosbuvir and ribavirin for the treatment of chronic hepatitis C infection of genotype 3 in patients who are treatment experienced, with or without compensated cirrhosis</span>,
                <span class="indication">In combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C infection of genotype 4</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Usual dose 60 mg once daily (for duration of treatment consult product literature).</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Reduce dose to 30&#8239;mg once daily with concomitant use of potent CYP3A4 inhibitors (e.g. atazanavir boosted with ritonavir, boceprevir, clarithromycin, cobicistat, itraconazole, ketoconazole, posaconazole, telaprevir, telithromycin, and voriconazole).</p> <p>Increase dose to 90&#8239;mg once daily with concomitant use of moderate CYP3A4 inducers (e.g. efavirenz).</p>
            </section>
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Daclatasvir is an inhibitor of the multifunctional protein NS5A, which is an essential component of the hepatitis C virus replication process.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid (toxicity in <i>animal</i> studies).</p>
            </section>
      </section>




      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain (in combination with sofosbuvir with or without ribavirin), alopecia (in combination with ribavarin and peginterferon alfa), alopecia (in combination with sofosbuvir with or without ribavirin), anaemia (in combination with ribavirin and peginterferon alfa), anaemia (in combination with sofosbuvir with or without ribavirin), anxiety (in combination with sofosbuvir with or without ribavirin), arthralgia (in combination with ribavirin and peginterferon alfa), arthralgia (in combination with sofosbuvir with or without ribavirin), blurred vision (in combination with ribavirin and peginterferon alfa), constipation (in combination with sofosbuvir with or without ribavirin), cough (in combination with sofosbuvir with or without ribavirin), decreased appetite (in combination with ribavirin and peginterferon alfa), decreased appetite (in combination with sofosbuvir with or without ribavirin), depression (in combination with sofosbuvir with or without ribavirin), diarrhoea (in combination with sofosbuvir with or without ribavirin), disturbance in attention (in combination with ribavirin and peginterferon alfa), dizziness (in combination with ribavirin and peginterferon alfa), dizziness (in combination with sofosbuvir with or without ribavirin),, dry mouth (in combination with sofosbuvir with or without ribavirin), dry skin (in combination with ribavirin and peginterferon alfa), dry skin (in combination with sofosbuvir with or without ribavirin), dyspnoea (in combination with sofosbuvir with or without ribavirin), flatulence (in combination with sofosbuvir with or without ribavirin), gastro-oesophageal reflux (in combination with sofosbuvir with or without ribavirin), headache (in combination with sofosbuvir with or without ribavirin), hot flush (in combination with sofosbuvir with or without ribavirin), insomnia (in combination with sofosbuvir with or without ribavirin), irritability (in combination with sofosbuvir with or without ribavirin), lymphopenia (in combination with ribavirin and peginterferon alfa), malaise (in combination with sofosbuvir with or without ribavirin), migraine (in combination with sofosbuvir with or without ribavirin), myalgia (in combination with ribavirin and peginterferon alfa), myalgia (in combination with sofosbuvir with or without ribavirin), nasal congestion (in combination with sofosbuvir with or without ribavirin), nausea (in combination with sofosbuvir with or without ribavirin), neutropenia (in combination with ribavirin and peginterferon alfa), pruritus (in combination with sofosbuvir with or without ribavirin),, pyrexia (in combination with ribavirin and peginterferon alfa), rash (in combination with ribavirin and peginterferon alfa), rash (in combination with sofosbuvir with or without ribavirin), reduced visual acuity (in combination with ribavirin and peginterferon alfa), vomiting (in combination with sofosbuvir with or without ribavirin),
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>If a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Decompensated liver disease
          </li>
          <li>
            hepatitis B virus co-infection
          </li>
          <li>
            human immunodeficiency virus co-infection
          </li>
          <li>
            organ transplant patients
          </li>
          <li>
            retreatment&#8212;efficacy not established in patients with prior exposure to a NS5A inhibitor
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Highly effective contraception required during and for 5 weeks after treatment.</p>
            </section>
      </section>












      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of DACLATASVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP101367"><a href="../medicinalForm/PHP101367.html" data-target="#PHP101367" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
